当前位置：药药网 / 数据中心 / 临床注释-2,变异和临床注释数据
尼古丁
临床注释ID
1139506787
药物名称(英)
nicotine
变异单倍型
CYP2A6*1A, CYP2A6*1B1, CYP2A6*1X2A, CYP2A6*2, CYP2A6*4A, CYP2A6*7, CYP2A6*9A, CYP2A6*10, CYP2A6*11, CYP2A6*12, CYP2A6*13, CYP2A6*14, CYP2A6*15, CYP2A6*17, CYP2A6*19, CYP2A6*20, CYP2A6*23, CYP2A6*24A, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28A, CYP2A6*35, CYP2A6*38
基因
CYP2A6
证据级别
1B
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Metabolism/PK
表现型类别
代谢/PK
分数
36
PMID计数
27
计数的证据
40
表现型
烟草使用障碍
表现型(英)
Tobacco Use Disorder
最新日期
2022/7/22 0:00:00
URL
https://www.pharmgkb.org/clinicalAnnotation/1139506787
专业人口(英)
专业人口
临床等位基因
id等位基因注释文本
784 *46 Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1A allele may have increased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
783 *38 Patients carrying two copies of the CYP2A6*38 allele or one copy of the *38 allele in combination with one copy of the *1A allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles but decreased metabolism as compared to patients carrying two copies of the *46 allele or one copy of the *46 allele in combination with one copy of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
782 *35 Patients carrying two copies of the CYP2A6*35 allele or one copy of the *35 allele in combination with one copy of the *1A, *9A or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele or patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
781 *28A Patients carrying two copies of the CYP2A6*28A allele or one copy of the *28A allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with one copy of the *28A allele in combination with one copy of the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
780 *27 Patients with two copies of the CYP2A6*27 allele or one copy of the *27 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with one copy of the *27 allele in combination with one copy of the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
779 *26 Patients with one copy of the CYP2A6*26 allele in combination with one copy of the *1A or *9A alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with one copy of the *26 allele in combination with one copy of the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
778 *25 Patients carrying one copy of the CYP2A6*25 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele or patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
777 *24A Patients with two copies of the CYP2A6*24A allele or one copy of the *24A allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with one copy of the *24A allele in combination with one copy of the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
776 *23 Patients carrying one copy of the CYP2A6*23 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele or patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
775 *20 Patients with two copies of the CYP2A6*20 allele or one copy of the *20 allele in combination with one copy of the *1A or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele or patients with one copy of the *1A allele in combination with the *9 or *12 alleles while patients with one copy of the *20 allele in combination with one copy of the *17 allele may have decreased metabolism of nicotine as compared to patients with two copies o the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
774 *19 Patients with two copies of the CYP2A6*19 allele or one copy of the *19 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
773 *17 Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1A, *4A, *20 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele while patients with two copies of the *17 allele or one copy of the *17 allele in combination with the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
772 *15 Patients with two copies of the CYP2A6*15 allele or one copy of the *15 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
771 *14 Patients carrying two copies of the CYP2A6*14 allele or one copy of the *14 allele in combination with one copy of the *1A allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
770 *13 Patients with two copies of the CYP2A6*13 allele or one copy of the *13 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
769 *12 Patients with two copies of the CYP2A6*12 allele or one copy of the *12 allele in combination with one copy of the *1A or *9A alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
768 *11 Patients with two copies of the CYP2A6*11 allele or one copy of the *11 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
767 *10 Patients with two copies of the CYP2A6*10 allele or one copy of the *10 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
766 *9A Patients with two copies of the CYP2A6*9A allele or one copy of the *9A allele in combination with one copy of the *1A, *4A, *12, *26 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele, while patients with two copies of the *9A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele and one copy of the *9A or *12 alleles. Patients with one copy of the *9A allele in combination with one copy of the *4A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with one copy of the *4A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
765 *7 Patients carrying two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1A or *4A alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
764 *4A Patients with two copies of the CYP2A6*4A allele or one copy of the *4A allele in combination with one copy of the *1A, *7, *9A or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1A, *14 or *38 alleles, while patients with one copy of the *4A allele in combination with one copy of the *9A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *4A allele in combination with one copy of the *1A allele. Patients with one copy of the *4A allele in combination with one copy of the *1A allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with the *9, *12, *14 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
763 *2 Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1A allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1A, *14 or *38 alleles or patients with one copy of the *1A allele in combination with the *9, *12, *41 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
762 *1x2 Patients with one copy of the CYP2A6*1x2 allele in combination with one copy of the *1A allele may have increased metabolism of nicotine as compared to patients with two copies of the *1A allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
761 *1A Patients with one copy of the CYP2A6*1A allele in combination with one copy of the *4 or *9A allele may have increased metabolism of nicotine as compared to patients with one copy of the *4A allele in combination with the *9A allele, or patients with two copies of the *9A allele. Patients with two copies of the *1A allele may have increased metabolism of nicotine as compared to patients with one copy of the *1A allele in combination with one copy of the *2, *4A, *7, *9A, *10, *11 *12, *13, *15, *17, *19, *20, *23, *24A, *25, *26, *27, *28A or *35 alleles or or patients with two copies of the *4A, *7, *9A, *10, *11 *12, *13, *15, *17, *19, *20, *24A, *27, *28A or *35 alleles or patients with the *4A/*7, *4A/*9 *4A/*17, *9/*12 *9/*26 or *17/*20 diplotypes but may have decreased metabolism as compared to patients with two copies of the *46 allele or one copy of the *1A allele in combination with the *46 or *1x2 alleles. However, conflicting evidence has been reported for *24A. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.
临床证据
id证据的ID总结
3262 827705096 CYP2A6 *46/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1A/*1A.
3261 1448601760 CYP2A6 *46/*46 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.
3260 827705098 CYP2A6 *1A/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1A/*1A.
3259 1451665300 CYP2A6 *1A/*2 + *1A/*4A + *1A/*9 + *1A/*12 + *1A/*17 + *1A/*20 + *1A/*23 + *1A/*24A + *1A/*25 + *1A/*26 + *1A/*27 + *1A/*28A + *1A/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 (assigned as intermediate and low activity phenotype) are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A +*1A/*46 + *46/*46 (assigned as normal metabolizer phenotype) .
3258 1451675840 CYP2A6 *1A + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *46.
3257 1451675720 CYP2A6 *1A + *46 + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4A.
3256 1451665280 CYP2A6 *1A/*46 + *46/*46 are associated with increased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3255 1451663040 CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A + *1A/*46 + *1A/*4A.
3254 827827796 CYP2A6 *1x2 is associated with increased metabolism of nicotine as compared to CYP2A6 *1A.
3253 1451822580 CYP2A6 *2 + *4A + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.
3252 827699412 CYP2A6 *4A/*9A + *9A/*9A are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A + *1A/*4A + *1A/*9A.
3251 827827639 CYP2A6 *1A/*20 + *17/*20 are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.
3250 981201993 CYP2A6 *4A/*4A + *4A/*7 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3249 827699021 CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1A.
3248 1451666264 CYP2A6 *24A is not associated with catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1A.
3247 1451666260 CYP2A6 *17 + *35 are associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1A.
3246 1451666225 CYP2A6 *35/*35 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3245 1451666180 CYP2A6 *1A/*35 + *9A/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3244 1451665780 CYP2A6 *1A/*2 + *1A/*4A + *1A/*17 + *1A/*20 + *1A/*23 + *1A/*24A + *1A/*25 + *1A/*26 + *1A/*27 + *1A/*28A + *1A/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*9 + *1A/*12A.
3243 1451665040 CYP2A6 *4A/*7 + *4A/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.
3242 1451664980 CYP2A6 *1A/*4A + *1A/*7 + *1A/*9 + *1A/*10 + *4A/*4A + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.
3241 1451664820 CYP2A6 *1A/*2 + *1A/*4A + *1A/*9 + *1A/*12 + *4A/*9 + *9/*9 + *9/*12 are associated with decreased clearance of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.
3240 827827654 CYP2A6 *20 is associated with decreased metabolism of coumarin and nicotine in healthy individuals as compared to CYP2A6 *1A.
3239 1451662880 CYP2A6 *7 is associated with decreased metabolism of coumarin or nicotine as compared to CYP2A6 *1A.
3238 1451662800 CYP2A6 *4A/*4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3237 1451409603 CYP2A6 *1A/*12 is associated with decreased concentrations of 3-hydroxycotinine as compared to CYP2A6 *1A/*1A.
3236 827824877 CYP2A6 *28A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.
3235 981344956 CYP2A6 *4A + *10 + *9A is associated with decreased plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT) when exposed to nicotine in healthy individuals as compared to CYP2A6 *1A.
3234 827824861 CYP2A6 *20 + *26 + *24A+ *9A + *27 + *17 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.
3233 1450824161 CYP2A6 *1A/*2 + *1A/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3232 1450809796 CYP2A6 *2 + *4A + *9 + *12 are associated with decreased clearance of cotinine and nicotine in healthy individuals as compared to CYP2A6 *1A.
3231 1447982613 CYP2A6 *4A/*17 + *9/*26 are associated with decreased metabolism of nicotine.
3230 827698978 CYP2A6 *1A/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A/*1A.
3229 981201935 CYP2A6 *4A is associated with decreased metabolism of nicotine as compared to CYP2A6 *1A.
3228 1451672860 Allele T is associated with decreased metabolism of nicotine as compared to allele C.
3227 1451667320 Allele T is associated with decreased metabolism of nicotine as compared to allele C.
3226 1451663080 Genotypes CT + TT are associated with decreased metabolism of nicotine as compared to genotype CC.
3225 1183703333 CYP2A6 poor metabolizer genotype is associated with decreased metabolism of nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.
3224 1183689165 CYP2A6 poor metabolizer genotype is associated with decreased ratio of plasma cotinine to urinary TNE when exposed to nicotine in smokers as compared to CYP2A6 normal metabolizer genotype.
3223 1183689160 CYP2A6 poor metabolizer genotype is associated with increased ratio of cotinine formation to removal when exposed to nicotine in nonsmokers as compared to CYP2A6 normal metabolizer genotype.
临床病史
id类型评论
1157 Update Change CYP2A6 named allele *1B1 to *46
1156 Update Change CYP2A6 named allele *1X2A to *1x2
1155 Update Converted *1X2B allele to *1X2A in preparation for CYP2A6's release on PharmVar
1154 Update Added descriptions for *14 and *38 alleles. Tagged *14 and *1x2 alleles as Limited Evidence. Removed no association VA on *18.
1153 Update Consolidated VAs from PMID 16952495 and added *11, *13 and *15 alleles
1152 Update Consolidated VAs from PMID 12844137
1151 Update Consolidated VAs from PMID 15993850
1150 Update Consolidated VAs from PMID 11779172
1149 Update Moved VA on coumarin to coumarin CA
1148 Update Consolidated VAs from PMID 15900015
1147 Update Added PMID 21597399 to evidence.
1146 Update Added PMID 34476898 to evidence
1145 Update Added PMID 19365400 to evidence and updated phenotype descriptions.
1144 Update Added PMID 19279561 to evidence, added *23, *25, *35 alleles to CA and updated phenotype descriptions.
1143 Update Added PMID 17220563 to evidence and updated relevant phenotype descriptions.
1142 Update Added PMID 15592323 to evidence. Minor edits to phenotype descriptions.
1141 Update Added PMID 15265511 to evidence
1140 Update Added PMID 11237731 to evidence
1139 Update Added PMID 10448083 to evidence
1138 Update Added PMID 31959879 to evidence
1137 Update CA score added as part of scoring system release. LOE assigned following curator review.
1136 Update Minor edits to phenotype descriptions
1135 Update Added PMID 30706508 to evidence, added new alleles and updated phenotype descriptions.
1134 Update Added PMIDs 27035242 and 27599351 to evidence and updated phenotype descriptions.
1133 Update Added PMID 15861035 to evidence and added *12 allele to annotation
1132 Update Removed PMIDs 25416559, 16402128 and 15940289 from this annotation for inclusion in new clinical annotations
1131 Update Evidence level change from 2B to 2A because CYP2A6 is a VIP

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3